Aurinia Pharmaceuticals

AUPH · NASDAQ

$16.74+$0.25 (+1.52%)TodayMarket closed · Oct 20, 7:58 PM ET

Prev close $16.49

AUPH analyst rating

HoldConsensus of 3 analysts over the last 12 months. 33% rate it a buy.

Strong buy0
Buy1
Hold2
Underperform0
Sell0

12-month price target · 9 analysts

Average $18.21 (+8.8% upside)

Low: $16.16
Now: $16.74
High: $22.05

Upgrades and downgrades

The latest rating actions, newest first

AUPH analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
RBC Capital	Aug 7, 2026	Maintains	Sector Perform	$15.00 → $16.00	56%
Leerink Partners	Dec 3, 2025	Downgrade	Outperform → Market Perform	$15.00 → $16.00	34%
Jefferies	Nov 7, 2025	Upgrade	Hold → Buy	$10.00 → $21.00	29%
RBC Capital	Nov 5, 2025	Downgrade	Outperform → Sector Perform	$9.00 → $15.00	56%

The case for and against

Updated Jan 19, 2026

Bull case

Aurinia Pharmaceuticals is projected to significantly increase its risk-adjusted product revenues, from $243.7 million in 2025 to $932.3 million by 2033, indicating strong market demand and growth potential. Additionally, the company anticipates aritinercept to contribute $15.4 million in revenue by 2030, with potential growth to $281.6 million by 2033, underpinned by a 20% probability of launch and a 15% peak penetration rate. Furthermore, the expected positive impact from the 2024 ACR LN guideline is anticipated to catalyze a new growth phase for LUPKYNIS, further enhancing the company's revenue prospects.

Bear case

Aurinia Pharmaceuticals has expressed challenges in achieving significant market penetration for LUPKYNIS, as evidenced by limited patient uptake and ongoing competition in the autoimmune disease therapeutics landscape. Additionally, the company's development of AUR200 may face obstacles, given the high costs associated with clinical trials and the complexities of demonstrating superior efficacy over existing treatments. Furthermore, Aurinia's financial metrics have indicated sustained operating losses, raising concerns about the company's long-term sustainability and capacity to fund ongoing research and development initiatives.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.